Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study

Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study

Abstract Background Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits compared with single-agent immunotherapy. Epacadostat, an indoleamine 2,3...

Full description

Bibliographic Details
Main Authors: Byoung Chul Cho, Irene Braña, Beatriz Cirauqui, Sercan Aksoy, Felix Couture, Ruey-Long Hong, Wilson H. Miller, Manuel Chaves-Conde, Margarida Teixeira, Lance Leopold, Mihaela Munteanu, Joy Yang Ge, Ramona F. Swaby, Brett G. M. Hughes
Format: Article
Language:English
Published: BMC 2024-07-01
Series:BMC Cancer
Subjects:
Pembrolizumab
PD-1
Immunotherapy
EXTREME
Cetuximab
Head and neck squamous cell carcinoma
Online Access:https://doi.org/10.1186/s12885-023-11316-0

Internet

https://doi.org/10.1186/s12885-023-11316-0

Similar Items